Subconjunctival Bevacizumab and Recurrent Pterygium

Phase 2

Completed

• Conditions: Recurrent Pterygium
• Interventions: Drug: Bevacizumab

• Registration Number: NCT01744756
• Lead Sponsor: Instituto de Olhos de Goiania

Brief Summary

A study to research whether subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.

Detailed Description

1. Pacients with recurrent pterygium

2. Anti-VEGF therapy -Bevacizumab

Study Timeline

• Study Start: 2012-02
• Primary Completion: 2012-07
• Study Completion: 2012-09
• Study First Submitted: 2012-11-29
• Status Verified: 2012-12
• Study First Submitted QC: 2012-12-06
• Last Update Submitted: 2012-12-06
• Study First Posted: 2012-12-07
• Last Update Posted: 2012-12-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Recurrent pterygium

Read More

Exclusion Criteria

• Pregnant or lactating women
• History of myocardial infarction
• History of stroke

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Subconjunctival Bevacizumab	Bevacizumab	One aplication of subconjunctival Bevacizumab 0,5 ml

Primary Outcome Measures

Name	Time	Method
Pterygium size after subconjunctival bevacizumab	8 weeks	-Size of recurrent pterygium (measured in mm) after injection

Secondary Outcome Measures

Name	Time	Method
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	8 weeks	-Number of patients with hyposphagma and irritative symptoms after subconjunctival injection

Trial Locations

Locations (1)

Instituto de Olhos de Goiania; 🇧🇷 Goiania, Goias, Brazil